DelveInsight’s “Graves Orbitopathy – Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of the Graves Orbitopathy Market, focusing on the autoimmune inflammatory condition affecting the orbit and extraocular muscles, often linked to Graves’ disease (hyperthyroidism). The report covers historical and forecasted trends in market size, epidemiology, treatment paradigms, and market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It explores current management options like corticosteroids and radiation, emerging biologics targeting IGF-1R and TSHR pathways, and the evolving Graves Orbitopathy Market, offering projections from 2020 to 2034 across the seven major markets (7MM). The report also delves into the epidemiology of Graves Orbitopathy (GO), also known as Thyroid Eye Disease (TED), the target patient population, unmet needs, market drivers, barriers, and growth opportunities, providing strategic insights for stakeholders in ophthalmology and endocrinology therapeutics.
Key Companies in the Graves Orbitopathy Competitive Landscape
The Graves Orbitopathy Market competitive landscape is shaped by leading companies such as Horizon Therapeutics (now Amgen), Viridian Therapeutics, QuidelOrtho, and Akeso Biopharma, which are advancing therapies including teprotumumab (Tepezza), VRDN-001, and TSHR antagonists for active and chronic GO. These players are intensifying R&D efforts, late-stage clinical trials, and real-world evidence generation to address vision-threatening inflammation and proptosis, capturing a larger share of the growing Graves Orbitopathy Market.
Graves Orbitopathy Overview
The global Graves Orbitopathy Market addresses an extrathyroidal manifestation of Graves’ disease, characterized by orbital inflammation, proptosis, diplopia, and potential vision loss, affecting quality of life and requiring multidisciplinary care. GO impacts 25-50% of Graves’ patients, with active disease (inflammation) transitioning to inactive (fibrosis) over 1-3 years. Current treatments include IV methylprednisolone (first-line; 50-70% response), rituximab (off-label), and surgery, but limitations in efficacy and side effects persist. Emerging biologics like IGF-1R inhibitors offer disease-modifying potential (70-80% response rates), with advances in biomarkers (e.g., anti-TSHR antibodies) and non-invasive monitoring propelling the Graves Orbitopathy Market Size toward targeted, steroid-sparing therapies.
Graves Orbitopathy Epidemiology and Target Population
Graves Orbitopathy affects ~300,000-500,000 patients in the 7MM, with an incidence of 20-50 per 100,000 annually, predominantly women (5-10:1 ratio) aged 40-60. Active moderate-to-severe GO comprises 20-30% of cases, often smoking-associated (increases risk 7-fold). The target population includes newly diagnosed (60%) and refractory/chronic (40%) patients, estimated at 150,000-250,000 in the 7MM, projected to grow 6-8% by 2034 due to rising autoimmune disorders, improved thyroid screening, and aging populations. Underdiagnosis in mild cases (40-50%) expands opportunities via enhanced awareness.
Graves Orbitopathy Market Drivers, Barriers, and Competitive Landscape
Key drivers of the Graves Orbitopathy Market include unmet needs for non-steroidal options, high disease burden (e.g., 30% vision impairment risk), and orphan drug incentives. The competitive landscape is nascent yet promising, dominated by Amgen’s teprotumumab (80% US share post-2020 approval) alongside pipeline challengers like Viridian (30% of late-stage assets). Barriers encompass high costs (USD 300,000+/course for teprotumumab), infusion-related reactions, access limitations in EU/Asia, and diagnostic delays. The Graves Orbitopathy Market is projected to grow at a CAGR of 12-15% through 2034, from ~USD 1.5 billion in 2023, driven by biologics approvals and multidisciplinary guidelines.
Graves Orbitopathy Emerging Therapies
The Graves Orbitopathy Market pipeline includes ~10-12 candidates, emphasizing IGF-1R/TSHR-targeted mAbs (e.g., VRDN-001 from Viridian; Phase 3 for proptosis), bispecifics, and small molecules. Late-stage trials focus on endpoints like clinical activity score (CAS) reduction and proptosis change, with innovations in subcutaneous formulations, combination with selenium, and gene therapies addressing chronic fibrosis.
Graves Orbitopathy Marketed Therapies
Marketed therapies in the Graves Orbitopathy Market are limited, with teprotumumab (Tepezza; Amgen; FDA/EMA-approved for active GO) as the only disease-modifying agent, achieving 70-80% proptosis reduction via 8 IV infusions. Supportive options include IV glucocorticoids (EUGOGO protocol; 4.5g cumulative dose) and tocilizumab (off-label; IL-6 inhibition). Surgical interventions (orbital decompression) are reserved for inactive disease (10-20% of cases).
Graves Orbitopathy Market Forecast and Report Highlights
The Graves Orbitopathy Market Size is forecasted to reach USD 4-5 billion by 2034, up from ~USD 1.5 billion in 2023, propelled by teprotumumab uptake, VRDN-003 approval (expected 2026), and expanded indications to mild GO. DelveInsight’s analysis projects a 20-25% rise in treated patients through awareness campaigns, with KOL insights, pricing/reimbursement models, and probabilistic forecasts guiding the Graves Orbitopathy Market.
Conclusion
The Graves Orbitopathy Market is transforming from symptomatic palliation to targeted immunomodulation, offering vision preservation and functional recovery for patients with this debilitating condition. As key companies advance biologics and optimize regimens, the landscape will shift toward early intervention and personalized care. By 2034, the Graves Orbitopathy Market Size will reflect broader adoption, emphasizing smoking cessation integration, global diagnostics, and reduced steroid reliance in endocrinology-ophthalmology collaboration.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Us
Kanishk
kkumar@delveinsight.com